92 related articles for article (PubMed ID: 6577744)
1. [Current perspectives in vaccine preparation].
Andersen H; Christiansen G; Christiansen C
Ugeskr Laeger; 1983 Aug; 145(34):2580-4. PubMed ID: 6577744
[No Abstract] [Full Text] [Related]
2. Recombinant DNA techniques in the pharmaceutical industry.
Winther MD
Med Lab Sci; 1985 Oct; 42(4):388-92. PubMed ID: 3866135
[No Abstract] [Full Text] [Related]
3. [Current trends in the use of DNA technologies].
Glazko VI; Domanskiĭ NN; Sozinov AA
Tsitol Genet; 1998; 32(5):80-93. PubMed ID: 9879119
[TBL] [Abstract][Full Text] [Related]
4. The development of and perspectives for genetic engineering of malaria parasites.
Waters AP; Janse CJ
Parassitologia; 1999 Sep; 41(1-3):453-9. PubMed ID: 10697902
[TBL] [Abstract][Full Text] [Related]
5. Recombinant vaccines for influenza virus.
Tripp RA; Tompkins SM
Curr Opin Investig Drugs; 2008 Aug; 9(8):836-45. PubMed ID: 18666031
[TBL] [Abstract][Full Text] [Related]
6. Microbial biotechnology in industry and medicine.
Keen H
Trans Med Soc Lond; 1981-1982; 98():53-8. PubMed ID: 6765274
[No Abstract] [Full Text] [Related]
7. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
[TBL] [Abstract][Full Text] [Related]
8. Impact of recombinant DNA technology in pharmacology.
Bruno F; Maggi A
Pharmacol Res Commun; 1985 Feb; 17(2):109-21. PubMed ID: 2581278
[No Abstract] [Full Text] [Related]
9. Genetically engineered vaccines: an overview.
Dertzbaugh MT
Plasmid; 1998; 39(2):100-13. PubMed ID: 9514708
[TBL] [Abstract][Full Text] [Related]
10. Introduction to gene technology.
Ritschel WA; Forusz H
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):453-67. PubMed ID: 7885071
[TBL] [Abstract][Full Text] [Related]
11. [Bioethical considerations of genetic engineering].
González-Fraguela ME
Rev Neurol; 2002 Oct 16-31; 35(8):701-4. PubMed ID: 12402218
[TBL] [Abstract][Full Text] [Related]
12. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
Liu Z; Chen YH
J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
[TBL] [Abstract][Full Text] [Related]
13. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
Bae K; Choi J; Jang Y; Ahn S; Hur B
Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
[TBL] [Abstract][Full Text] [Related]
14. Genetic immunization: applying recombinant DNA technology in the immune system to develop new vaccines.
Barry MA
Curr Opin Drug Discov Devel; 1999 Mar; 2(2):118-28. PubMed ID: 19649937
[TBL] [Abstract][Full Text] [Related]
15. Technology, medicine & health, Part 3. Therapeutics for tomorrow.
Davidson SN
Healthc Forum J; 1995; 38(1):52-60. PubMed ID: 10154288
[No Abstract] [Full Text] [Related]
16. [Problems of vaccine preparation].
Lafontaine A
Pathol Microbiol (Basel); 1969; 34(3):218-39. PubMed ID: 5379716
[No Abstract] [Full Text] [Related]
17. Strategies of constructing recombinant vaccines.
Sałamaszyńska-Guz A; Klimuszko D
Pol J Vet Sci; 2009; 12(1):133-9. PubMed ID: 19459451
[TBL] [Abstract][Full Text] [Related]
18. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology.
Middlebrook JL
Adv Drug Deliv Rev; 2005 Jun; 57(9):1415-23. PubMed ID: 15896873
[TBL] [Abstract][Full Text] [Related]
19. A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases.
Kaslow DC
Trans R Soc Trop Med Hyg; 2004 Oct; 98(10):593-601. PubMed ID: 15289096
[TBL] [Abstract][Full Text] [Related]
20. rDNA based pharmaceuticals (selected information).
Ghosh M; Khape AR; Bannur BB
Hindustan Antibiot Bull; 1993; 35(3-4):219-55. PubMed ID: 7960931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
